Drug intelligence / Profile preview

BA301

Development stage: Preclinical
Lead developer: T-Cypher Bio
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

BA301 is a bispecific T-cell engager (TCE) being developed by T-Cypher Bio for the treatment of various autoimmune diseases. The therapeutic candidate is designed to target TC301, a specific antigen, and simultaneously bind to the CD3 receptor on T cells to redirect their activity. In the context of autoimmune therapy, this mechanism is typically intended to deplete pathogenic cell populations, such as autoreactive B cells or T cells, that drive disease pathology. BA301 is currently in the discovery and lead selection phase of development.

Targets

BlaR (Beta-lactamase regulatory protein BlaR)CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on BA301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BA301.

Explore the full profile